These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 24428087)

  • 1. D-dimer as a tumor marker in pre-operative assessment of adnexal masses.
    Worasethsin P; Narkwichean A
    J Med Assoc Thai; 2013 Nov; 96(11):1395-400. PubMed ID: 24428087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preoperative evaluation of D-dimer and CA 125 levels in differentiating benign from malignant ovarian masses.
    Gadducci A; Baicchi U; Marrai R; Ferdeghini M; Bianchi R; Facchini V
    Gynecol Oncol; 1996 Feb; 60(2):197-202. PubMed ID: 8631538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blood clotting activation analysis for preoperative differentiation of benign versus malignant ovarian masses.
    Amirkhosravi A; Bigsby G; Desai H; Rivera-Amaya M; Coll E; Robles-Carrillo L; Faust P; Waters A; Meyer T; Reyes E; Langer F; Francis JL
    Blood Coagul Fibrinolysis; 2013 Jul; 24(5):510-7. PubMed ID: 23406663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel approach to predict the likelihood of specific ovarian tumor pathology based on serum CA-125: a multicenter observational study.
    Van Calster B; Valentin L; Van Holsbeke C; Zhang J; Jurkovic D; Lissoni AA; Testa AC; Czekierdowski A; Fischerová D; Domali E; Van de Putte G; Vergote I; Van Huffel S; Bourne T; Timmerman D
    Cancer Epidemiol Biomarkers Prev; 2011 Nov; 20(11):2420-8. PubMed ID: 21908724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The role of D-dimer in diagnosis of ovarian cancer].
    Kanayama N
    Nihon Sanka Fujinka Gakkai Zasshi; 1991 May; 43(5):485-8. PubMed ID: 2056222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. External validation of the adapted Risk of Malignancy Index incorporating tumor size in the preoperative evaluation of adnexal masses.
    van den Akker PA; Zusterzeel PL; Aalders AL; Snijders MP; Samlal RA; Vollebergh JH; Kluivers KB; Massuger LF
    Eur J Obstet Gynecol Reprod Biol; 2011 Dec; 159(2):422-5. PubMed ID: 21824712
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The risk of malignancy index in discrimination of adnexal masses.
    Ulusoy S; Akbayir O; Numanoglu C; Ulusoy N; Odabas E; Gulkilik A
    Int J Gynaecol Obstet; 2007 Mar; 96(3):186-91. PubMed ID: 17280665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preoperative determination of CASA (Cancer Associated Serum Antigen) and CA-125 for the discrimination between benign and malignant pelvic tumor mass: a prospective study.
    Sehouli J; Akdogan Z; Heinze T; Könsgen D; Stengel D; Mustea A; Lichtenegger W
    Anticancer Res; 2003; 23(2A):1115-8. PubMed ID: 12820357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human epididymis protein 4 offers superior specificity in the differentiation of benign and malignant adnexal masses in premenopausal women.
    Holcomb K; Vucetic Z; Miller MC; Knapp RC
    Am J Obstet Gynecol; 2011 Oct; 205(4):358.e1-6. PubMed ID: 21722869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Adnexal masses management: a prospective multicentric observational study].
    Huchon C; Bats AS; Bensaïd C; Junger M; Nos C; Chatellier G; Lécuru F
    Gynecol Obstet Fertil; 2008 Nov; 36(11):1084-90. PubMed ID: 18964176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The measurement of plasma D-dimer (DD) levels in the follow-up of patients with ovarian cancer.
    Gadducci A; Marrai R; Baicchi U; Ferdeghini M; Fanucchi A; Facchini V; Genazzani AR
    Anticancer Res; 1995; 15(6B):2683-6. PubMed ID: 8669847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Introduction of new Tumor Marker Age Score in clinical practice: Validity evaluation for differentiation benign from malignant adnexal masses.
    Ladjević IL; Terzić M; Ladjević N; Dotlić J; Pilić I; Bila J; Knezević N; Milenković S; Maricić S; Arsenović N; Brndusić N; Nikolić B
    Acta Chir Iugosl; 2012; 59(3):49-56. PubMed ID: 23654006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Use of Human Epididymis 4 and Cancer Antigen 125 Tumor Markers in the Benign or Malignant Differential Diagnosis of Pelvic or Adnexal Masses.
    Dolgun ZN; Kabaca C; Karateke A; İyibozkurt C; İnan C; Altıntaş AS; Karadağ C
    Balkan Med J; 2017 Apr; 34(2):156-162. PubMed ID: 28418343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and validation of a model that includes two ultrasound parameters and the plasma D-dimer level for predicting malignancy in adnexal masses: an observational study.
    Stukan M; Badocha M; Ratajczak K
    BMC Cancer; 2019 Jun; 19(1):564. PubMed ID: 31185938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of size of the adnexal mass on the accuracy of frozen section diagnosis.
    Geomini PM; Zuurendonk LD; Bremer GL; de Graaff J; Kruitwagen RF; Mol BW
    Gynecol Oncol; 2005 Nov; 99(2):362-6. PubMed ID: 16051343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Should cut-off values of the risk of malignancy index be changed for evaluation of adnexal masses in Asian and Pacific populations?
    Yavuzcan A; Caglar M; Ozgu E; Ustun Y; Dilbaz S; Ozdemir I; Yildiz E; Gungor T; Kumru S
    Asian Pac J Cancer Prev; 2013; 14(9):5455-9. PubMed ID: 24175841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Application values of four risk of malignancy indices in the preoperative evaluation of patients with adnexal masses].
    Lou HY; Meng H; Zhu QL; Zhang Q; Jiang YX
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2010 Jun; 32(3):297-302. PubMed ID: 20602883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urinary gonadotropin peptide (UGP) and serum CA 125 in gynaecologic practice, a clinical prospective study.
    Schutter EM; Mijatovic V; Kok A; Van Kamp GJ; Verstraeten R; Verheijen RH
    Anticancer Res; 1999; 19(6C):5551-7. PubMed ID: 10697615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the Risk of Malignancy Index in daily clinical management of adnexal masses.
    van den Akker PA; Aalders AL; Snijders MP; Kluivers KB; Samlal RA; Vollebergh JH; Massuger LF
    Gynecol Oncol; 2010 Mar; 116(3):384-8. PubMed ID: 19959215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of malignancy index in the preoperative evaluation of patients with adnexal masses.
    Andersen ES; Knudsen A; Rix P; Johansen B
    Gynecol Oncol; 2003 Jul; 90(1):109-12. PubMed ID: 12821350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.